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Prions are proteinaceus infectious agents associated to
invariable fatal neurodegenerative disorders named trans-
missible spongiform encephalopathies or prion diseases.
The mechanism associated with disease propagation lays
on post-translation modifications of the cellular prion
protein (PrPC), which acquires altered conformation,
form aggregates and is resistant to proteolysis. PrPC is a
cell surface glycosyphosphatidylinositol (GPI)-anchored
protein of 208-209 aminoacids which is codified by a sin-
gle exon and whose expression is developmentally regu-
lated. In adult animals PrPC is highly expressed in the
central nervous system but peripheral nervous system
and other organs or tissues also express this protein.
Initial experiments conducted with PrPC-null mice
established that this protein is absolutely necessary to
propagate prion infection. Remarkably, these animals had
no gross anatomical abnormalities or behavior alterations
although higher neuronal sensitivity to stress conditions
such us seizures and hypoxic-ischemic injury are present.
These data pointed that PrPC would be unnecessary for
embryonic development or some compensatory mechan-
ism might be present in these animals. In fact, the later
hypothesis was supported by findings that demonstrated
that deletion of specific PrPC domains cause severe neu-
rodegeneration in mice.
The use of cellular models led to the characterization of
PrPC ligands and related signaling pathways allowing the
definition of PrPC cellular functions. We identified three
major ligands for PrPC, two proteins of the extracellular
matrix, laminin and vitronectin, and a secreted co-chaper-
one the stress inducible protein 1 (STI1) or Hop (its
human homologue). Comparative experiments using neu-
rons derived from wild type and PrPC-null mice demon-
strated that PrPC binding to vitronectin promoted axonal
growth in dorsal root ganglion neurons (DRG). In addi-
tion, PrPC interaction with laminin activated metabotropic
glutamate receptors, Ca2+ mobilization and PKC activation
promoting neuronal plasticity and memory formation in
rats. STI1 was the most explored PrPC ligand. The PrPC-
STI1 engagement induces PKA an ERK1/2 activation,
which increase neuronal survival and differentiation. The
signaling pathways modulated by PrPC-STI1 also included
Ca2+ influx by activation of a-7 nicotinic acetylcholine
receptor, induction of PI3K and mTOR. These last two
pathways were associated to increased protein synthesis.
An increment on the self-renewed of neuronal progenitors
is also modulated by PrPC-STI1 engagement.
The co-chaperone STI1 is known to interact with PrPC
at the neuronal membrane and recently we demonstrated
that this protein is abundantly secreted by astrocytes.
Secreted STI1 plays an autocrine activity upon astrocytes
modulating their proliferation and differentiation. The
mechanism associated with STI1 secretion is under eva-
luation but preliminary results indicated that this protein
is secreted by microvesicles derived from multivesicular
bodies.
The involvement of PrPC and STI1/Hop in cellular sur-
vival and differentiation raised questions regarding their
involvement in tumoral processes. In fact, the literature
has been pointed that PrPC expression contributes to can-
cer progression and resistance to various cancer therapies.
STI1/Hop expression was also associated with the prolif-
eration of tumor cells. Our data pointed that STI1 secreted
by glioblastoma cells has an autocrine function mediating
proliferation of these cells by binding to PrPC. We are pre-
sently evaluating how to interfere with the PrPC-STI1
binding in order to modulate tumor growth.
Together our results point that PrPC-STI1 engagement
is an interesting therapeutic target for both neurodegen-
eration and cancer and investments should be done to
address these issues.
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